NOX3 and Jeune syndrome: Carriers of a rare NADPH oxidase 3 (NOX3) variants were demonstrated to have increased apoptosis of methimazole-treated granulocytes [26] and genetic analysis may be a component of the personalised management of ATD in GD in future.